Literature DB >> 31282571

Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity.

R L Venchiarutti1,2, M J Solomon1,2,3,4, C E Koh1,2,3,4, J M Young1,2,3, D Steffens1,2.   

Abstract

BACKGROUND: Pelvic exenteration (PE) provides a potentially curative option for advanced or recurrent malignancy confined to the pelvis. A clear (R0) resection margin is the strongest prognostic factor predicting long-term survival, driving most technical advances in PE surgery. The aim of this cohort study was to describe changing trends in extent of resection, postoperative complications, mortality and overall survival after PE surgery.
METHODS: Consecutive patients who underwent PE for advanced or recurrent pelvic malignancy at a single institution in Sydney, Australia, were identified. The cohort was divided into three groups based on time periods reflecting annual surgical volume: 1994-2006 (20 or fewer procedures per year), 2007-2013 (21-50 procedures per year) and 2014-2017 (over 50 procedures per year). Primary outcomes were extent of resection, postoperative complications, 60-day mortality and 3-year overall survival. Secondary outcomes were patient characteristics, receipt of neoadjuvant therapy and duration of hospital stay.
RESULTS: There were increases over time in rates of lateral and posterior compartment resections (P < 0·001), and bony pelvis (P = 0·002) and neurovascular (P < 0·001) excision. For patients undergoing reconstruction, the proportion receiving vertical rectus abdominus myocutaneous flaps increased significantly (P = 0·005). Rates of wound infection, dehiscence, and abdominal and pelvic collections increased over the study interval. Short-term mortality decreased, and 1- and 3-year survival rates improved.
CONCLUSION: Technical and surgical advancements have led to more complex PE resections, with R0 and mortality rates improving with higher annual volume. There were associated increases in intraoperative blood loss and postoperative morbidity.
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31282571     DOI: 10.1002/bjs.11203

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group.

Authors:  Alexandre Doussot; Dewi Vernerey; Eric Rullier; Jérémie H Lefevre; Hélène Meillat; Eddy Cotte; Guillaume Piessen; Jean-Jacques Tuech; Yves Panis; Diane Mege; Aurélia Meurisse; Berardino De Bari; Bruno Heyd; Zaher Lakkis
Journal:  Ann Surg Oncol       Date:  2020-06-04       Impact factor: 5.344

2.  PRehabIlitatiOn with pReoperatIve exercise and educaTion for patients undergoing major abdominal cancer surgerY: protocol for a multicentre randomised controlled TRIAL (PRIORITY TRIAL).

Authors:  Daniel Steffens; Jane Young; Bernhard Riedel; Rachael Morton; Linda Denehy; Alexander Heriot; Cherry Koh; Qiang Li; Adrian Bauman; Charbel Sandroussi; Hilmy Ismail; Mbathio Dieng; Nabila Ansari; Neil Pillinger; Sarah O'Shannassy; Sam McKeown; Derek Cunningham; Kym Sheehan; Gino Iori; Jenna Bartyn; Michael Solomon
Journal:  BMC Cancer       Date:  2022-04-22       Impact factor: 4.638

3.  State-of-the-art surgery for recurrent and locally advanced rectal cancers.

Authors:  Mufaddal Kazi; Vivek Sukumar; Ashwin Desouza; Avanish Saklani
Journal:  Langenbecks Arch Surg       Date:  2021-08-02       Impact factor: 3.445

4.  Regional variance in treatment and outcomes of locally invasive (T4) rectal cancer in Australia and New Zealand: analysis of the Bi-National Colorectal Cancer Audit.

Authors:  Tessa L Dinger; Hidde M Kroon; Luke Traeger; Sergei Bedrikovetski; Andrew Hunter; Tarik Sammour
Journal:  ANZ J Surg       Date:  2022-05-03       Impact factor: 2.025

Review 5.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.